FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 10:46:06 2024-05-22 am EDT | ||
| 0.65 EUR / 0.66 EUR | -2.24% |
|
| Current month | -82.09% | ||
| 1 month | -82.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 0.71 | +5.97% |
| 24-05-21 | 0.67 | +8.06% |
| 24-05-20 | 0.62 | -6.06% |
| 24-05-17 | 0.66 | -14.29% |
| 24-05-16 | 0.77 | -10.47% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 04:50 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2P4S |
| ISIN | DE000JK2P4S9 |
| Date issued | 2024-02-23 |
| Strike | 478.8 $ |
| Maturity | Unlimited |
| Parity | 52.08 : 1 |
| Emission price | 2.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.54 € |
|---|---|
| Lowest since issue | 0.62 € |
| Spread | 0.01 € |
| Spread % | 1.52% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
442
USD
Average target price
462.8
USD
Spread / Average Target
+4.71%
- Stock Market
- Certificates
- Certificat
